Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23860942 | 1.00 | CRBN (0.55) | CRBNIKZF2GSPT1CYP2C19KCNH2 | |
| SCHEMBL26538312 | 0.88 | CRBN (0.55) | CRBNIKZF2GSPT1CYP2C19KCNH2 | |
| SCHEMBL30168890 | 0.88 | CRBN (0.54) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL23861002 | 0.88 | CRBN (0.54) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30168941 | 0.87 | CRBN (0.55) | CRBNIKZF2DDB1IKZF1 | |
| SCHEMBL23860913 | 0.87 | CRBN (0.55) | CRBNIKZF2DDB1IKZF1 | |
| SCHEMBL23877207 | 0.87 | CRBN (0.55) | CRBNIKZF2GSPT1CYP2C19KCNH2 | |
| SCHEMBL30168996 | 0.87 | CRBN (0.55) | CRBNIKZF2GSPT1CYP2C19KCNH2 | |
| SCHEMBL23860965 | 0.86 | CRBN (0.54) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30168854 | 0.86 | CRBN (0.54) | CRBNIKZF2IKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | claimed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | CRBN 411/4885IKZF2 71/4885GSPT1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.